CEA SGLT2i class_manuscript TRACKED 20200720.docx (211.1 kB)
Download file

Assessing the cost-effectiveness of SGLT2i in type 2 diabetes mellitus: a comprehensive economic evaluation using clinical trial and real-world evidence.

Download (211.1 kB)
journal contribution
posted on 03.09.2020, 10:49 by Phil McEwan, Hayley Bennett, Kamlesh Khunti, John Wilding, Christopher Edmonds, Marcus Thuresson, Eric Wittbrodt, Peter Fenici, Mikhail Kosiborod
AIMS: The economic burden of diabetes is driven by the management of vascular complications. Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have demonstrated reductions in cardiovascular and renal complications, including hospitalisation for heart failure (HHF) and renal disease progression, in randomised clinical trials. The objective of this study was to evaluate the cost-effectiveness of the SGLT2i class versus standard of care in type 2 diabetes mellitus (T2DM), using evidence from both clinical trial and real-world studies. METHODS: An established T2DM model was adapted to use contemporary outcomes evidence from real-world studies and randomised controlled trial evaluations of SGLT2i and extrapolated over a lifetime for HHF, myocardial infarction, stroke, end-stage renal disease, and all-cause mortality. The economic analysis considered adults with T2DM, with and without established cardiovascular disease, and was conducted over a lifetime from the perspective of the healthcare payer in the UK, US, and China, discounted at country-specific rates. RESULTS: SGLT2i were consistently associated with increased treatment costs, reduced complication costs and gains in quality-adjusted life years driven by differences in projected life expectancy, cardiovascular and microvascular morbidity and weight loss. SGLT2i were estimated to be cost-saving or cost-effective at relevant thresholds for the overall population in the UK, US and China, with the cost-effectiveness being greatest in higher risk subgroups. CONCLUSIONS: The findings highlight the need to take into account cost savings from reducing common, morbid and preventable T2DM complications when considering the cost of diabetes medications. This article is protected by copyright. All rights reserved.

Funding

AstraZeneca

History

Citation

Diabetes, Obesity and Metabolism: a journal of pharmacology and therapeutics, 2020, https://doi.org/10.1111/dom.14162

Author affiliation

Diabetes Research Centre, College of Life Sciences

Version

AM (Accepted Manuscript)

Published in

Diabetes, Obesity and Metabolism: a journal of pharmacology and therapeutics

Publisher

Wiley

issn

1462-8902

eissn

1463-1326

Acceptance date

29/07/2020

Copyright date

2020

Available date

03/08/2021

Spatial coverage

England

Language

eng

Publisher version

https://dom-pubs.onlinelibrary.wiley.com/doi/full/10.1111/dom.14162